Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Relapsed/refractory DLBCL presents significant treatment challenges, particularly in the veteran population.
• Understanding treatment patterns and outcomes is crucial for improving patient care.

Purpose of the Study:

• To characterize treatment practices and clinical outcomes for veterans diagnosed with relapsed/refractory diffuse large B-cell lymphoma.
• To analyze the types and sequences of treatments administered after second-line therapy.
• To evaluate progression-free survival and overall survival in this patient cohort.

Main Methods:

• Retrospective analysis of data from the Veteran Affairs Cancer Registry System and electronic health records.
• Identification of patients with relapsed/refractory DLBCL who completed second-line treatment between 2000 and 2016.
• Classification of treatments as aggressive or nonaggressive and application of Kaplan-Meier methods for survival analysis.

Main Results:

• A total of 270 patients received second-line treatment, with a median follow-up of 9.7 months.
• Patients received an average of 2.7 treatment regimens, with 219 classified as aggressive and 251 as nonaggressive.
• Median progression-free survival was 5.2 months, and median overall survival was 9.5 months, with 16.3% proceeding to bone marrow transplant.

Conclusions:

• Current treatment paradigms for relapsed/refractory DLBCL in veterans yield modest survival outcomes.
• There is a critical need for the development and earlier implementation of more effective and less toxic therapeutic options.
• Optimizing treatment strategies earlier in the disease course may improve long-term survival for these patients.